Latest news

• Pfizer/BioNTech to develop a booster dose for their COVID-19 vaccine

  BioNTech is also planning to publish an additional analysis of its Pifzer-partnered vaccine's efficacy against the coronavirus strain identified in South Africa.

• Pfizer/BioNTech's COVID-19 vaccine found to be effective against UK virus variant

  BioNTech is planning to publish analysis on vaccine's efficacy against South African variant

• Pifzer, BioNTech eye October approval for mRNA-based COVID-19 vaccine

  Companies share additional phase 1 safety and tolerability data

• CHMP recommends new Keytruda dosing schedule

  Other PD-1/PD-L1 inhibitors approved for use are AstraZeneca’s Imfinzi, Pifzer and Merck’s Bavencio and Roche’s Tecentriq, and the latter is currently being explored in a

• Novartis claims FDA breakthrough status for leukaemia treatment

  Also waiting in the wings could be volasertib from Boehringer Ingelheim, which is currently in phase III clinical trials, and Pifzer's Mylotarg, which would be reintroduced to the market after